Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Germline predisposition (cancer predisposition and myeloid genes) stratifying prognosis

Therapy-related myeloid neoplasms (t-MN) are classified by treatment history rather than molecular features, and the role of germline predisposition remains poorly defined. Integrating clinical characteristics, prior regimens and genomic profiling in 100 patients, the authors detected somatic abnormalities in 89.8% and germline variants in 32.3% (19.8% in cancer predisposition genes, 14.6% in myeloid genes). Stratification by germline landscape defined three prognostically distinct subgroups. Carriers of germline cancer predisposition variants were enriched for TP53 mutations, complex karyotypes and adverse prognosis. The authors advocate incorporating the germline landscape into disease classification and risk stratification.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Identifying germline predisposition in t-MN goes beyond prognostic value: it opens the way to targeted surveillance and preventive strategies in at-risk relatives. The link between predisposition variants, TP53 mutations and poor prognosis after chemotherapy exposure is clinically meaningful. Based on 100 patients, these subgroups require validation before incorporation into classifications.

Analysis by Dr Thibaut Benquey